Gene Therapy Restores Hearing in Deaf Patients

Researchers have reported significant success with an experimental gene therapy aimed at restoring hearing in individuals born with autosomal recessive deafness 9 (DFNB9), a condition caused by mutations in the OTOF gene. This therapy utilizes a harmless adenovirus carrying a functional version of the OTOF gene to enable the production of the essential otoferlin protein in the inner ear.

The study, involving 42 participants of various ages, found that approximately 90% experienced hearing restoration within weeks, with continued improvement over six months. For some, these benefits have lasted over two years, enabling them to hear whispers and even learn to speak. This marks a pivotal moment, offering a new treatment for genetic hearing loss.

This innovative approach is considered very safe, though long-term monitoring is ongoing. The success of this therapy, particularly for a rare condition, is encouraging researchers to explore similar methods for other forms of genetic deafness and potentially for age-related or noise-induced hearing loss in the future. Early intervention is deemed crucial for optimal outcomes.